Peroxisome proliferator-activated receptor agonists with phenethylphenylphthalimide skeleton derived from thalidomide-related liver X receptor antagonists: Relationship between absolute configuration and subtype selectivity

Bioorganic and Medicinal Chemistry

Volumn 19, Issue 10, 2011, Pages 3156-3172

  Motoshima, Kazunori ^a   Ishikawa, Minoru ^a   Hashimoto, Yuichi ^a   Sugita, Kazuyuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Molecular design; Nuclear receptor; PPAR agonist; Subtype selectivity

Indexed keywords

3 [4 [2 (4 ACETYLAMINOPHENYL)ETHYL]PHENYL]PROPIONIC ACID ETHYL ESTER; 3 [4 [2 (4 AMINOPHENYL)ETHYL]PHENYL]PROPIONIC ACID ETHYL ESTER; 3 [4 [2 [4 (1,3 DIOXO 1,3 DIHYDRO ISOINDOL 2 YL)PHENYL]ETHYL]PHENYL]PENTANOIC ACID ETHYL ESTER; 3 [4 [2 [4 (1,3 DIOXO 1,3 DIHYDRO ISOINDOL 2 YL)PHENYL]ETHYL]PHENYL]PROPIONIC ACID ETHYL ESTER; 4 (BROMOMETHYL)BENZOIC ACID BUTYL ESTER; 4 [2 (4 ACETYLAMINOPHENYL)ETHYL]BENZOIC ACID METHYL ESTER; 4 [2 (4 ACETYLAMINOPHENYL)VINYL]BENZOIC ACID METHYL ESTER; 4 [2 (4 AMINOPHENYL)ETHYL]BENZOIC ACID BUTYL ESTER; 4 [2 (4 NITROPHENYL)ETHENYL]BENZOIC ACID BUTYL ESTER; 4 [2 [4 (1,3 DIOXO 1,3 DIHYDRO ISOINDOL 2 YL)PHENYL]ETHYL]BENZOIC ACID; 4 [2 [4 (1,3 DIOXO 1,3 DIHYDRO ISOINDOL 2 YL)PHENYL]ETHYL]BENZOIC ACID BUTYL ESTER; 4 METHYLBENZOIC ACID BUTYL ESTER; 5 [4 [2 (4 ACETYLAMINO PHENYL)ETHYL]PHENYL]PENTANOIC ACID ETHYL ESTER; 5 [4 [2 (4 AMINOPHENYL)ETHYL]PHENYL]PENTANOIC ACID ETHYL ESTER; 5 [4 [2 [4 (1,3 DIOXO 1,3 DIHYDRO ISOINDOL 2 YL)PHENYL]ETHYL]PHENYL]PENTANOIC ACID ETHYL ESTER; 7 [4 [2 (4 ACETYLAMINOPHENYL)ETHYL]PHENYL]HEPTANOIC ACID ETHYL ESTER; 7 [4 [2 (4 AMINOPHENYL)ETHYL]PHENYL]HEPTANOIC ACID ETHYL ESTER; 7 [4 [2 [4 (1,3 DIOXO 1,3 DIHYDRO ISOINDOL 2 YL)PHENYL]ETHYL]PHENYL]HEPTANOIC ACID ETHYL ESTER; [[4 ( BUTOXYOXYCARBONNYL)PHENYL]METHYL]TRIPHENYLPHOSPHONIUM BROMIDE; [[4 (METHOXYCARBONYL)PHENYL]METHYL]TRIPHENYL PHOSPHONIUM BROMIDE; ETHOXYCARBONYLMETHYL TRIPHENYL PHOSPHONIUM BROMIDE; ETHOXYCARBONYLPENTYL TRIPHENYL PHOSPHONIUM BROMIDE; ETHOXYCARBONYLPROPYL TRIPHENYL PHOSPHONIUM BROMIDE; LIVER X RECEPTOR; N [4 [2 (4 FORMYLPHENYL)ETHYL]PHENYL]ACETAMIDE; N [4 [2 (4 HYDROXYMETHYLPHENYL)ETHYL]PHENYL]ACETAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHENETHYLPHENYLPHTHALIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BROMINATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG HYDROLYSIS; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; REPORTER GENE; STRUCTURE ACTIVITY RELATION;

CELL LINE; DRUG DESIGN; HUMANS; LIGANDS; MODELS, MOLECULAR; ORPHAN NUCLEAR RECEPTORS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PHTHALIMIDES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP; THALIDOMIDE;

EID: 79956201861     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2011.03.065     Document Type: Article

References (44)

1. Nuclear Receptors Nomenclature Committee. Cell 1999, 97, 161.
2. G. Krey, O. Braissant, F. L'Horset, E. Kalkhoven, M. Perroud, M.G. Parker, and W. Wahli Mol. Endocrinol. 11 1997 779
3. J. Berger, and D.E. Moller Annu. Rev. Med. 53 2002 409
4. J.N. Feige, L. Gelman, L. Michalik, B. Desvergne, and W. Wahli Prog. Lipid Res. 45 2006 120
5. S. Mandard, M. Müller, and S. Kersten Cell. Mol. Life Sci. 61 2004 393
6. J.C. Fruchart, B. Staels, and P. Duriez Pharmacol. Res. 44 2001 345
7. D. Auboeuf, J. Rieusset, L. Fajas, P. Vallier, V. Frering, J.P. Riou, B. Staels, J. Auwerx, M. Laville, and H. Vidal Diabetes 46 1997 1319
8. M.L. Sznaidman, C.D. Haffner, P.R. Maloney, A. Fivush, E. Chao, D. Goreham, M.L. Sierra, C. LeGrumelec, H.E. Xu, V.G. Montana, M.H. Lambert, T.M. Willson, W.R. Oliver Jr., and D.D. Sternbach Bioorg. Med. Chem. Lett. 13 2003 1517
9. C.H. Lee, P. Olson, A. Hevener, I. Mehl, L.W. Chong, J.M. Olefsky, F.J. Gonzalez, J. Ham, H. Kang, J.M. Peters, and R.M. Evans Proc. Natl. Acad. Sci. U.S.A. 103 2006 3444
10. T. Tanaka, J. Yamamoto, S. Iwasaki, H. Asaba, H. Hamura, Y. Ikeda, M. Watanabe, K. Magoori, R.X. Ioka, K. Tachibana, Y. Watanabe, Y. Uchiyama, K. Sumi, H. Iguchi, S. Ito, T. Doi, T. Hamakubo, M. Naito, J. Auwerx, M. Yanagisawa, T. Kodama, and J. Sakai Proc. Natl. Acad. Sci. U.S.A. 100 2003 15924
11. B. Hulin, P.A. McCarthy, and E.M. Gibbs Curr. Pharm. Des. 2 1996 85
12. A.R. Saltiel, and J.M. Olefsky Diabetes 45 1996 1661
13. Y. Hashimoto Arch. Pharm. Chem. Life Sci. 341 2008 536
14. Y. Hashimoto Bioorg. Med. Chem. 10 2002 461
15. Y. Hashimoto Cancer Chemother. Pharmacol. 52 2003 S16
16. Y. Hashimoto, A. Tanatani, K. Nagasawa, and H. Miyachi Drugs Future 29 2004 383
17. Y. Hashimoto Curr. Med. Chem. 5 1998 163
18. Y. Hashimoto Mini-Rev. Med. Chem. 2 2002 543
19. E.V. Koonin, Y.I. Wolf, and G.P. Karev Nature 420 2002 218
20. N.V. Grishin J. Struct. Biol. 134 2001 167
21. M.A. Koch, L.-O. Wittenberg, S. Basu, D.A. Jeyaraj, E. Gourzoulidou, K. Reinecke, A. Odermatt, and H. Waldmann Proc. Natl. Acad. Sci. U.S.A. 101 2004 16721
22. J.B. Bartlett, K. Dredge, and A.G. Dalgleish Nat. Rev. Cancer 4 2004 314
23. H. Miyachi, A. Azuma, A. Ogasawara, E. Uchimura, N. Watanabe, Y. Kobayashi, F. Kato, M. Kato, and Y. Hashimoto J. Med. Chem. 40 1997 2858
24. H. Miyachi, A. Ogasawara, A. Azuma, and Y. Hashimoto Bioorg. Med. Chem. 5 1997 2095
25. R. Shimazawa, H. Sano, A. Tanatani, H. Miyachi, and Y. Hashimoto Chem. Pharm. Bull. 52 2004 498
26. T. Noguchi, H. Sano, R. Shimazawa, A. Tanatani, H. Miyachi, and Y. Hashimoto Bioorg. Med. Chem. Lett. 14 2004 4141
27. T. Noguchi, R. Shimazawa, K. Nagasawa, and Y. Hashimoto Bioorg. Med. Chem. Lett. 12 2002 1043
28. H. Sano, T. Noguchi, A. Tanatani, H. Miyachi, and Y. Hashimoto Chem. Pharm. Bull. 52 2004 1021
29. H. Sano, T. Noguchi, A. Tanatani, Y. Hashimoto, and H. Miyachi Bioorg. Med. Chem. 13 2005 3079
30. T. Noguchi-Yachide, A. Aoyama, M. Makishima, H. Miyachi, and Y. Hashimoto Bioorg. Med. Chem. Lett. 17 2007 3957
31. T. Noguchi-Yachide, H. Miyachi, H. Aoyama, A. Aoyama, M. Makishima, and Y. Hashimoto Chem. Pharm. Bull. 55 2007 1750
32. K. Dodo, A. Aoyama, T. Noguchi-Yachide, M. Makishima, H. Miyachi, and Y. Hashimoto Bioorg. Med. Chem. 16 2008 4272
33. K. Motoshima, T. Noguchi-Yachide, K. Sugita, Y. Hashimoto, and M. Ishikawa Bioorg. Med. Chem. 17 2009 5001
34. S. Sou, S. Mayumi, H. Takahashi, R. Yamasaki, S. Kadoya, M. Sodeoka, and Y. Hashimoto Bioorg. Med. Chem. Lett. 10 2000 1081
35. S. Sou, H. Takahashi, R. Yamasaki, H. Kagechika, Y. Endo, and Y. Hashimoto Chem. Pharm. Bull. 49 2001 791
36. H. Takahashi, S. Sou, R. Yamasaki, M. Sodeoka, and Y. Hashimoto Chem. Pharm. Bull. 48 2000 1494
37. K. Motoshima, M. Ishikawa, K. Sugita, and Y. Hashimoto Biol. Pharm. Bull. 32 2009 1618
38. B.A. Janowski, P.J. Willy, T.R. Devi, J.R. Falck, and D.J. Mangelsdorf Nature 383 1996 728
39. J. Kasuga, D. Yamasaki, Y. Araya, A. Nakagawa, M. Makishima, T. Doi, Y. Hashimoto, and H. Miyachi Bioorg. Med. Chem. 14 2006 8405
40. G.M. Morris, D.S. Goodsell, R.S. Halliday, R. Huey, W.E. Hart, R.K. Belew, and A.J. Olson J. Comput. Chem. 19 1998 1639
41. Y. Nagai, and T. Kusumi Tetrahedron Lett. 36 1995 1853
42. T. Yabuuchi, T. Ooi, and T. Kusumi Chirality 9 1997 550
43. T. Yabuuchi, and T. Kusumi J. Org. Chem. 65 2000 397
44. M. Makishima, A.Y. Okamoto, J.J. Repa, H. Tu, R.M. Learned, A. Luk, M.V. Hull, K.D. Lustig, D.J. Mangelsdorf, and B. Shan Science 284 1999 1362